Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 8, 2020

View Archived Issues

SH-229: phase II data in combination with daclatasvir in Chinese patients with chronic HCV

Incyte initiates phase I study of INCB-099280 in solid tumors

Development of BI-1467335 discontinued for diabetic retinopathy

Phase III study evaluates NA-831 plus OPV as prevention and treatment of early onset of COVID-19

Dracen Pharmaceuticals begins first-in-human study of DRP-104

BeiGene starts phase I study of SARS-CoV-2 neutralizing antibody BGB-DXP-593

New candidate breast cancer risk gene identified

JNK as a novel therapeutic target in cholestatic liver diseases

CRISPR immune suppression strengthens CRISPR gene therapy

mTOR-targeting metabolite discovered

AKG for A-OK aging

GYS2 identified as potential new prognostic biomarker in HCC

QKI-7 targeting restores endothelial cell function and improves vascular complications in diabetes

New Nav1.8 channel blockers patented by Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical

Adlai Nortye describes new PD-1/PD-L1 interaction inhibitors

Shenzhen Targetrx Biotechnology discovers RET inhibitors

An integrated pipeline for rapid discovery and validation of MAbs against viral pathogens

New PCSK9 inhibitors presented by the Wisconsin Alumni Research Foundation

Enterin identifies new PTP-1B inhibitors

Amplia receives ethics committee clearance for phase I trial of FAK inhibitor AMP-945

Inhibitory decoy gene created to inhibit Galpha-q for uveal melanoma treatment

Valneva advances chikungunya vaccine candidate VLA-1553 into phase III

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...